Shriram Ct Scan & Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 07-07-2024
- Paid Up Capital ₹ 7.45 M
as on 07-07-2024
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 205.74%
(FY 2021)
- Profit 1963.03%
(FY 2021)
- Ebitda 689.55%
(FY 2021)
- Net Worth 78.07%
(FY 2021)
- Total Assets 99.71%
(FY 2021)
About Shriram Ct Scan & Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.45 M, as per Ministry of Corporate Affairs (MCA) records.
Prasad Joshi, Rajenn Pandit, Dhananjay Kutwal, and Seven other members serve as directors at the Company.
- CIN/LLPIN
U85100PN2013PTC148450
- Company No.
148450
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shriram Ct Scan & Diagnostics?
Board Members(10)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasad Joshi  | Director | 14-Aug-2013 | Current |
| Rajenn Pandit | Director | 16-Aug-2013 | Current |
| Dhananjay Kutwal | Director | 16-Aug-2013 | Current |
| Sharad Dhaigude | Director | 16-Aug-2013 | Current |
| Kirankumar Nale | Director | 16-Aug-2013 | Current |
| Sachin Gosavi | Director | 16-Aug-2013 | Current |
Financial Performance and Corporate Structure Insights of Shriram Ct Scan & Diagnostics.
Shriram Ct Scan & Diagnostics Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 205.74% increase. The company also saw a substantial improvement in profitability, with a 1963.03% increase in profit. The company's net worth Soared by an impressive increase of 78.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shriram Ct Scan & Diagnostics?
In 2019, Shriram Ct Scan & Diagnostics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Abhinav Mri & Diagnostics Private Limited
Active
14 years 2 months Prasad Joshi, Rajenn Pandit and 6 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shriram Ct Scan & Diagnostics?
Unlock and access historical data on people associated with Shriram Ct Scan & Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 24, 2014, Shriram Ct Scan & Diagnostics has raised a total of ₹ 7.35 M, with the most recent deal valued at ₹ 1.95 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
